S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
NASDAQ:PROK

ProKidney (PROK) Stock Price, News & Analysis

$1.64
+0.19 (+13.10%)
(As of 04/11/2024 ET)
Today's Range
$1.45
$1.65
50-Day Range
$1.20
$1.77
52-Week Range
$1.12
$13.51
Volume
2.88 million shs
Average Volume
334,383 shs
Market Capitalization
$376.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

ProKidney MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
479.3% Upside
$9.50 Price Target
Short Interest
Bearish
31.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of ProKidney in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.65) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.39 out of 5 stars

Medical Sector

2359th out of 2,796 stocks

Biological Products, Except Diagnostic Industry

358th out of 432 stocks

PROK stock logo

About ProKidney Stock (NASDAQ:PROK)

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

PROK Stock Price History

PROK Stock News Headlines

ProKidney (NASDAQ:PROK) Trading 13.1% Higher
Think AI Is Big? Then You Should See This…
If you think AI is big, then you have got check out something we call Imperium…  Elon Musk calls it “amazing.” Bill Gates says Imperium is “one of the most powerful technologies of the 21st century.” And we expect it to grow 320,000% within three years.
ProKidney assumed with an Equal Weight at Morgan Stanley
Think AI Is Big? Then You Should See This…
If you think AI is big, then you have got check out something we call Imperium…  Elon Musk calls it “amazing.” Bill Gates says Imperium is “one of the most powerful technologies of the 21st century.” And we expect it to grow 320,000% within three years.
PROK Mar 2024 7.500 call
ProKidney (NASDAQ: PROK)
BTIG Reaffirms Their Buy Rating on ProKidney (PROK)
PROK Jan 2024 10.000 call
ProKidney GAAP EPS of -$0.18
ProKidney Reports Third Quarter Financial Results
See More Headlines
Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/12/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PROK
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$16.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+479.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-35,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4.84) per share

Miscellaneous

Free Float
126,162,000
Market Cap
$376.12 million
Optionable
Optionable
Beta
1.08
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Timothy A. Bertram D.V.M. (Age 69)
    Ph.D., Founder
    Comp: $970.4k
  • Mr. Todd C. Girolamo Esq. (Age 59)
    J.D., M.B.A., Chief Legal Officer & Corporate Secretary
    Comp: $600.17k
  • Dr. Bruce Culleton M.D.
    CEO & Director
  • Dr. Glenn Schulman M.P.H.
    Pharm. D., Pharm.D., Senior Vice President of Investor Relations
  • Ms. Mary Weger (Age 65)
    Chief People Officer
  • Dr. Joseph M. Stavas M.D.
    M.P.H., Senior VP and Head of Global Clinical Development & Interventional Procedures
  • Dr. Darin J. Weber Ph.D. (Age 56)
    Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access
  • Mr. Nikhil L. Pereira-Kamath
    Chief Business Officer
  • Mr. Richard Williams
    Senior Vice President of Information Technology
  • Dr. Aparna Sahoo M.D.
    VP & Head of Global Clinical Development

PROK Stock Analysis - Frequently Asked Questions

Should I buy or sell ProKidney stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PROK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROK, but not buy additional shares or sell existing shares.
View PROK analyst ratings
or view top-rated stocks.

What is ProKidney's stock price target for 2024?

3 brokers have issued twelve-month price targets for ProKidney's shares. Their PROK share price targets range from $3.00 to $16.00. On average, they predict the company's share price to reach $9.50 in the next year. This suggests a possible upside of 479.3% from the stock's current price.
View analysts price targets for PROK
or view top-rated stocks among Wall Street analysts.

How have PROK shares performed in 2024?

ProKidney's stock was trading at $1.78 on January 1st, 2024. Since then, PROK shares have decreased by 7.9% and is now trading at $1.64.
View the best growth stocks for 2024 here
.

When is ProKidney's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PROK earnings forecast
.

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) announced its quarterly earnings data on Thursday, March, 21st. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10.

What ETF holds ProKidney's stock?

ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio.

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PROK) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners